Drug Profile
KW 2449
Alternative Names: KW-2449Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyowa Kirin Pharmaceutical Development
- Developer Kyowa Hakko Kirin; Kyowa Kirin Pharmaceutical Development
- Class Antineoplastics; Indazoles; Piperazines; Small molecules
- Mechanism of Action Aurora kinase inhibitors; Bcr-abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jul 2010 Discontinued - Phase-I/II for Acute myeloid leukaemia in USA (PO)
- 30 Mar 2010 Suspended - Phase-I/II for Acute myeloid leukaemia in USA (PO)
- 11 Dec 2007 Interim efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a Phase-I trial and a Preclinical trial in Cancer presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007) ,